CC 5013 hydrochloride
- CAS No.
- 1243329-97-6
- Chemical Name:
- CC 5013 hydrochloride
- Synonyms
- Lenalidomide HCl;CC5013 hydrochloride;CC-5013 hydrochloride;CC 5013 hydrochloride;RevliMid hydrochloride;LenalidoMide (hydrochloride)
- CBNumber:
- CB82666651
- Molecular Formula:
- C13H14ClN3O3
- Molecular Weight:
- 295.72
- MDL Number:
- MFCD26960943
- MOL File:
- 1243329-97-6.mol
- MSDS File:
- SDS
| storage temp. | Store at -20°C |
|---|---|
| solubility | insoluble in H2O; ≥1.83 mg/mL in EtOH; ≥72.2 mg/mL in DMSO |
| form | solid |
| FDA UNII | 46Q7T54YCJ |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Danger |
| Hazard statements | H360-H373 |
| Precautionary statements | P260-P314-P501 |
CC 5013 hydrochloride price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ApexBio Technology | A3547 | Lenalidomidehydrochloride | 1243329-97-6 | 50mg | $90 | 2021-12-16 | Buy |
| ApexBio Technology | A3547 | Lenalidomidehydrochloride | 1243329-97-6 | 100mg | $120 | 2021-12-16 | Buy |
| ApexBio Technology | A3547 | Lenalidomidehydrochloride | 1243329-97-6 | 250mg | $150 | 2021-12-16 | Buy |
| ApexBio Technology | A3547 | Lenalidomidehydrochloride | 1243329-97-6 | 500mg | $180 | 2021-12-16 | Buy |
| Crysdot | CD31004121 | Lenalidomidehydrochloride 98+% | 1243329-97-6 | 1g | $217 | 2021-12-16 | Buy |
CC 5013 hydrochloride Chemical Properties,Uses,Production
Biological Activity
lenalidomideis a derivative of thalidomide introduced in 2004. lenalidomide (revlimid, cc-5013) is a tnf-α secretion inhibitor with ic50 of 13 nm.
in vitro
lenalidomide strongly induces il-2 and sil-2r production. lenalidomide-induced tyrosine phosphorylation of cd28 on t cells is followed by a down-stream activation of nf-κb [2]. lenalidomide and pomalidomide inhibits autoubiquitination of crbn in hek293 t cells expressing thalidomide-binding competent wild-type crbn, but not thalidomide-binding defective crbn (yw/aa). overexpression of crbn wild-type protein, but not crbn (yw/aa) mutant protein, in kms12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and irf4 expression and increases in p21(waf-1) expression. long-term selection for lenalidomide resistance in h929 myeloma cell lines is accompanied by a reduction in crbn, while in df15r myeloma cells resistant to both pomalidomide and lenalidomide, crbn protein is undetectable [3].
in vivo
pharmacokinetic studies evaluated doses of 0.5, 1.5, 5, and 10 mg/kg iv and 0.5 and 10 mg/kg doses for ip and oral routes. liquid chromatography-tandem mass spectrometry was used to quantify lenalidomide in plasma, brain, lung, liver, heart, kidney, spleen, and muscle [4]. treatment with either thalidomide or lenalidomide attenuated weight loss, enhanced motor performance, decreased motor neuron cell death, and significantly increased the life span in g93a transgenic mice [5].
IC 50
value: 13 nm [1] lenalidomideis a derivative of thalidomide introduced in 2004. lenalidomide (revlimid, cc-5013) is a tnf-α secretion inhibitor with ic50 of 13 nm. in vitro: lenalidomide strongly induces il-2 and sil-2r production. lenalidomide-induced tyrosine phosphorylation of cd28 on t cells is followed by a down-stream activation of nf-κb [2]. lenalidomide and pomalidomide inhibits autoubiquitination of crbn in hek293 t cells expressing thalidomide-binding competent wild-type crbn, but not thalidomide-binding defective crbn (yw/aa). overexpression of crbn wild-type protein, but not crbn (yw/aa) mutant protein, in kms12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and irf4 expression and increases in p21(waf-1) expression. long-term selection for lenalidomide resistance in h929 myeloma cell lines is accompanied by a reduction in crbn, while in df15r myeloma cells resistant to both pomalidomide and lenalidomide, crbn protein is undetectable [3]. in vivo: pharmacokinetic studies evaluated doses of 0.5, 1.5, 5, and 10 mg/kg iv and 0.5 and 10 mg/kg doses for ip and oral routes. liquid chromatography-tandem mass spectrometry was used to quantify lenalidomide in plasma, brain, lung, liver, heart, kidney, spleen, and muscle [4]. treatment with either thalidomide or lenalidomide attenuated weight loss, enhanced motor performance, decreased motor neuron cell death, and significantly increased the life span in g93a transgenic mice [5]. toxicity: international staging system iii received a combination therapy of lenalidomide (15 mg, day 1 - 21) with dexamethasone (40 mg, day 1, 8, 15, 22). after 4 days on chemotherapy, he experienced worsened dyspnea and was urgently hospitalized because of acute respiratory failure [6].
CC 5013 hydrochloride Preparation Products And Raw materials
Raw materials
Preparation Products
CC 5013 hydrochloride Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +8613564774135 | zijue.cai@tsbiochem.com | United States | 19881 | 58 |
| Amadis Chemical Company Limited | 571-89925085 | sales@amadischem.com | China | 131957 | 58 |
| LETOPHARM LIMITED | +86-21-5821 5861 | sales@letopharm.com | China | 2384 | 58 |
| SPIRO PHARMA | eric_feng1954@126.com | China | 9248 | 55 | |
| Musechem | +1-800-259-7612 | info@musechem.com | United States | 4660 | 60 |
| Absin Bioscience Inc. | 021-38015121 15000105423 | wulan@absin.cn | China | 24731 | 58 |
| MedBioPharmaceutical Technology Inc | 021-69568360 18916172912 | order@med-bio.cn | China | 8140 | 58 |
| TargetMol Chemicals Inc. | 4008200310 | marketing@tsbiochem.com | China | 24644 | 58 |
| Shanghai YuZn Pharm. Technology Co.,Ltd. | 15921286451; 15921286451 | 2010681527@qq.com | China | 5112 | 58 |
| Taizhou Zhongzhi Biotechnology Co., Ltd | 13012344321 | 3995296515@qq.com | China | 7996 | 58 |
View Lastest Price from CC 5013 hydrochloride manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-10-24 | Lenalidomide hydrochloride
1243329-97-6
|
US $1520.00-1980.00 / mg | 10g | TargetMol Chemicals Inc. |
-
- Lenalidomide hydrochloride
1243329-97-6
- US $1520.00-1980.00 / mg
- TargetMol Chemicals Inc.